Business Wire

MA-PRECISELY

17.5.2023 15:31:33 CEST | Business Wire | Press release

Share
Precisely Announces EngageOne RapidCX, Revolutionizing Customer Communications Management for Highly Regulated Industries

Precisely, the global leader in data integrity, today announced the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005070/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Precisely, the global leader in data integrity, announces the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market. (Photo: Business Wire)

RapidCX empowers organizations to provide a better, more effective customer experience through data-driven, personalized, communications. This is particularly important for highly regulated industries such as financial services, insurance, and telecommunications, where the pressure is on to deliver more personalized and dynamic customer experiences to stay competitive, while also navigating increasingly complicated regulatory requirements.

Announced at the Trust ‘23 Data Integrity Summit, RapidCX allows organizations to solve challenges such as disjointed customer communications, compliance with changing regulations, and siloed legacy systems to:

  • Improve Efficiencies – replace manual customer experience processes with an automated solution that enables business users to harness data from across all systems.
  • Enhance Customer Engagement – capture data-driven insights to quickly and easily personalize and automate omnichannel communications, including e-mails, SMS messages, chatbot conversations, interactive video and more.
  • Enable Better Governance – ensure compliance with end-to-end communications tracking, delivery tracing, and archiving. Easy-to-manage governance controls make even complicated industry regulations easier to follow.

“The launch of RapidCX is a significant industry event and a real game changer for Precisely, particularly in highly regulated markets,“ said Kaspar Roos, Founder & CEO at Aspire. “Precisely has brought together a wide variety of standalone capabilities into a comprehensive, fully managed cloud-based platform, providing a simplified way for customers to get access to modern customer-focused technologies without the need for extensive integration. The launch positions Precisely favorably to meet the needs of a new generation of CCM buyers found in marketing, customer experience, and the line-of-business.”

The announcement of the new platform is well-timed, with customer loyalty being harder to come by in recent years due to shifts in consumer behavior, rising competition, and economic pressures. In fact, a recent PwC survey showed that more than half of consumers (55%) would stop buying from a company, even if they otherwise liked them, after having several bad experiences – with a further 8% saying they would stop after just one negative experience.

With the rollout of RapidCX, organizations worldwide can now easily and dynamically deliver satisfying, personalized experiences, no matter how, where or when the customer chooses to interact. When combined with the Precisely portfolio of data integrity solutions, organizations can ensure they are powering customer communications delivery with trusted data, helping to win lasting loyalty and, ultimately, accelerate business growth.

“Businesses can no longer apply a one-size-fits-all approach to customer engagement. Today's customers expect extraordinary experiences, and trusted data is the cornerstone for delivering them,” said Greg Van den Heuvel, Executive Vice President and General Manager – Engage Solutions at Precisely. “Forward-thinking organizations are turning to cloud hosted integrated customer engagement platforms, fueled with accurate, consistent, and contextual data, to revolutionize their approach to customer communications.”

Learn more about RapidCX here.

About Precisely

Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005070/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye